Bech 2003

1 Treatments

**Studied treatment** repaglinide initiated at 0.5 mg per meal, increased to 1 mg after 4 weeks if fasting plasma glucose exceeded 7.8 mmol/l.

**Control treatment** placebo

**Concomittant treatments** -

2 Patients

**Patients** pharmacotherapy-naive patients with Type 2 diabetes

**Inclusion criteria** -

**Exclusion criteria** -

3 Methods

**Blinding** double-blind

**Design** Parallel groups

**Centers** multicentre

**Geographical area** -

**Sizes** 253/0

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References